Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: A prospective, observational study

Pain Physician

Volumn 7, Issue 4, 2004, Pages 431-437

  Manchikanti, Laxmaiah ^a,c   Damron, Kim S ^b   McManus, Carla D ^b   Barnhill, Renee C ^b  

^a University of Louisville School of Medicine   (United States)

^b Ambulatory Surgery Center   (United States)

^c NONE   (United States)

Author keywords

Abuse; Controlled substance abuse; Drug dependence; Illicit drug use; Misuse

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CANNABIS; ILLICIT DRUG; METHAMPHETAMINE; OPIATE;

ADULT; AGED; ANAMNESIS; ANXIETY DISORDER; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE DURATION; DRUG ABUSE; DRUG URINE LEVEL; DRUG USE; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PROSPECTIVE STUDY; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; SELF REPORT; SOMATIZATION;

EID: 9444280220     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Verhaak PFM, Kerssens JJ, Dekker J et al. Prevalence of chronic benign pain disorder among adults: A review of the literature. Pain 1998; 77:231-239.
2. Van Den Kerkhof EG, Hopman WM, Towheed TE et al. The impact of sampling and measurement on the prevalence of self-reported pain in Canada. Pain Res Manage 2003; 8:157-163.
3. Moulin DE, Clark AJ, Speechley M et al. Chronic pain in Canada - prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manage 2002; 7:179-184.
4. Elliott AM, Smith BH, Hannaford PC et al. The course of chronic pain in the community: Results of a 4-year follow-up study. Pain 2002; 99:299-307.
5. Yeung SS, Genaidy A, Deddens J et al. Prevalence of musculoskeletal symptoms in single and multiple body regions and effects of perceived risk of injury among manual handling workers. Spine 2002; 27:2166-2172.
6. Andersson HI, Ejlertsson G, Leden I et al. Chronic pain in a geographically defined general population: Studies of differences in age, gender, social class, and pain localization. Clin J Pain 1993; 9:174-182.
7. Ferrell BR, Ferrell BA (eds). Pain in the elderly. A report of the task force on pain in the elderly of the international association for the study of pain. IASP Press, Seattle, 1996.
8. Cassidy D, Carroll L, Cotê P: The Saskatchewan Health and Back Pain Survey. The prevalence of low back pain and related disability in Saskatchewan Adults. Spine 1998; 23:1860-1867.
9. Côté DC, Cassidy JD, Carroll L. The Saskatchewan Health and Back Pain Survey. The prevalence of neck pain and related disability in Saskatchewan adults. Spine 1998; 23:1689-1698.
10. Lawrence RC, Helmick CG, Arnett FC. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-799.
11. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain, 4th edition. American Pain Society, Glenview, 1999.
12. Joranson DE, Carrow GM, Ryan KM et al. Pain management and prescription monitoring. J Pain Symptom Manage 2002; 23: 231-238.
13. American Medical Association. Curtailing prescription drug abuse while preserving therapeutic use: American Medical Association recommendations for drug control policy. In: Wilford BB, ed. Balancing the Response to Prescription Drug Abuse, Chicago, American Medical Association, 1990, pp 273-298.
14. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: A systematic review. J Pain Symptom Manage 2003; 26:1026-1048.
15. Luo X; Pietrobon R, Hey L. Patterns and trends in opioid use among individuals with back pain in the United States. Spine 2004; 29:884-891.
16. Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 2002; 18: 355-365.
17. Turk DC, Brody MC, Okifuji EA. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain 1994; 59:201-208.
18. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 1992; 8: 77-85.
19. Chabal C, Erjavec MK, Jacobson L et al. Prescription opiate abuse in chronic pain patients: Clinical criteria, incidence, and predictors. Clin J Pain 1997; 13:150-155.
20. Atluri S, Sudarshan G. Evaluation of abnormal urine drug screens among patients with chronic non-malignant pain treated with opioids. Pain Physician 2003; 6:407-409.
21. Katz NP, Sherburne S, Beach M et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003; 97:1097-1102.
22. Manchikanti L, Pampati V, Damron K et al. Prevalence of illicit drug use in patients without controlled substance abuse in interventional pain management. Pain Physician 2003; 6:173-178.
23. Manchikanti L, Pampati V, Damron K et al. Prevalence of opioid abuse in interventional pain medicine practice settings: A randomized clinical evaluation. Pain Physician 2001; 4:358-365.
24. Manchikanti L, Pampati V, Damron K. Prevalence of prescription drug abuse and dependency in patients with chronic pain in western Kentucky. J KY Med Assoc 2003; 101:511-517.
25. Manchikanti L, Beyer C, Damron K et al. A comparative evaluation of illicit drug use in patients with or without controlled substance abuse in interventional pain management. Pain Physician 2003; 6:281-285.
26. Fishman SM, Wilsey B, Yang J et al. Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage 2000; 20:293-307.
27. Gajraj N, Hervias-Sanz M. Opiate abuse or undertreatment? Clin J Pain 1998; 14:90-91.
28. Prescription Drug Monitoring: Strategies to Promote Treatment and Deter Prescription Drug Abuse. Hearings of Subcommittee on Health House Energy and Commerce Committee, March 4, 2004.
29. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National Survey of Substance Abuse Treatment Services (N-SSATS): 2002. Data on Substance Abuse Treatment Facilities, DASIS Series: S-19, DHHS Publication No. (SMA) 03-3777, Rockville, MD, 2003.
30. Atluri S, Boswell M, Hansen H et al. Guidelines for the use of controlled substances in the management of chronic pain. Pain Physician 2003; 6:233-257.
31. Manchikanti L, Singh V, Damron KS et al. Screening for controlled substance abuse in interventional pain management settings: Evaluation of an assessment tool. Pain Physician 2003; 6:425-433.
32. Manchikanti L, Pampati V, Damron KS et al. Evaluation of variables in illicit drug use: Does a controlled substance abuse screening tool identify illicit drug use? Pain Physician 2004; 7:71-76.
33. Savage SR. Assessment for addiction in pain-treatment settings. Clin J Pain 2002; 18:S28-S38.
34. Kirsh KL, Whitcomb LA, Donaghy K et al. Abuse and addiction in medically ill patients with pain: Attempts at clarification of terms and empirical study. Clin J Pain 2002; 18S52-S60.
35. Compton P, Darakjian J, Miotto K. Screening for addiction in patients with chronic pain and "problematic" substance use: Evaluation of a pilot assessment tool. J Pain Symptom Manage 1998; 16:355-363.
36. Robinson RC, Gatchel RJ, Polatin P et al. Screening for problematic prescription opioid use. Clin J Pain 2001; 17:220-228.
37. Chabal C, Jacobson L, Mariano A et al. Narcotics for chronic pain? Yes or no. A useless dichotomy. Am Pain Soc J 1992; 1: 276-281.
38. Chabal C, Jacobson L, Mariano A et al. The psychosocial impact of opioid treatment. Am Pain Soc J 1992; 1:289-291.
39. Chabal C, Jacobson L, Mairano AJ et al. Pseudoaddiction or pseudo label? Clin J Pain 1998; 14:90-91.
40. Manchikanti L, Fellows B. Psychological screening in low back pain. In Manchikanti L, Slipman CW, Fellows B (eds), Interventional Pain Management: Low Back Pain - Diagnosis and Treatment. ASIPP Publishing, Paducah, KY 2002; 167-176.
41. Tollison CD, Langley JC. Pain Patient Profile (P-3) Manual National Computer Systems, Minneapolis, 1995.
42. Compton WM, Grant BJ, Colliver JD et al. Prevalence of Marijuana Use Disorders in the United States: 1991-1992 and 2001-2002. JAMA 2004; 291:2114-2121.
43. Johnston LD, O'Malley PM, Bachman JG. Monitoring the Future National Survey Results on Drug Use, 1975-2002. Bethesda, Md: National Institute on Drug Abuse; 2003.
44. Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. Addiction 2000;95:1621-1630.
45. Lehman WE, Simpson DD. Employee substance abuse and on-the-job behaviors. J Appl Psychol 1992;77:309-321.
46. Lynskey MT, Health AC, Bucholz KK, et al. Escalation of drug use in early onset cannabis users vs co-twin controls. JAMA 2003;289:427-433.
47. National Highway Traffic Safety Administration. Traffic Safety Facts 2001. Washington, DC: National Highway Traffic Safety Administration; 2001.
48. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001;103:2805-2809.
49. Tashkin DP. Pulmonary complications of smoked substance abuse. West J Med 1990;152:525-530.
50. Cami J, Farré M. Mechanisms of Disease: Drug addiction. NEJM 2003; 349:975-986.
51. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998;352:1611-1616.
52. Budney AJ, Hughes JR, Moore BA et al. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 2001;58: 917-924.
53. Office of National Drug Control Policy, Drug Facts: Cocaine, May 2002.
54. Sarnyai Z, Shaham Y, Heinrichs SC. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 2001;53: 209-243.
55. Farre M, de la Torre R, Gonzalez ML et al. Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. J Pharmacol Exp Ther 1997;283:164-176.
56. Mello NK, Mendelson JH. Cocaine's effects on neuroendocrine systems: clinical and preclinical studies. Pharmacol Biochem Behav 1997;57:571-599.
57. Mendelson JH, Mello NK. Management of cocaine abuse and dependence. N Engl J Med 1996; 334:965-972.